Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery

Skin is an attractive target for delivery of genetic therapies and vaccines. However, new approaches are needed to access this tissue more effectively. Here, we describe a new delivery technology based on arrays of structurally precise, micron-scale silicon projections, which we term microenhancer arrays (MEAs). In a human clinical study, these devices effectively breached the skin barrier, allowing direct access to the epidermis with minimal associated discomfort and skin irritation. In a mouse model, MEA-based delivery enabled topical gene transfer resulting in reporter gene activity up to 2,800-fold above topical controls. MEA-based delivery enabled topical immunization with naked plasmid DNA, inducing stronger and less variable immune responses than via needle-based injections, and reduced the number of immunizations required for full seroconversion. Together, the results provide the first in vivo use of microfabricated devices to breach the skin barrier and deliver vaccines topically, suggesting significant clinical and practical advantages over existing technologies.

[1]  B. Wahrén,et al.  Protection against influenza virus challenge by topical application of influenza DNA vaccine. , 2001, Vaccine.

[2]  T. Greten,et al.  Monitoring antigen-specific T cells using MHC-Ig dimers. , 2001, Current protocols in immunology.

[3]  R. Dubner,et al.  Validity and sensitivity of ratio scales of sensory and affective verbal pain descriptors: Manipulation of affect by diazepam , 1978, Pain.

[4]  P. Khavari,et al.  Immunization via hair follicles by topical application of naked DNA to normal skin , 1999, Nature Biotechnology.

[5]  L. Goldsmith,et al.  Topical application of viral vectors for epidermal gene transfer. , 1997, The Journal of investigative dermatology.

[6]  G. Grove,et al.  Computerized evaporimetry using the DermaLab® TEWL probe , 1999 .

[7]  G. Cevc,et al.  Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. , 1998, Vaccine.

[8]  R. Akhurst,et al.  Liposome-medicated gene transfer and expression via the skin. , 1995, Human molecular genetics.

[9]  M. Allen,et al.  Microfabricated microneedles for gene and drug delivery. , 2000, Annual review of biomedical engineering.

[10]  D. Tang,et al.  Vaccination onto bare skin , 1997, Nature.

[11]  R. Purcell,et al.  Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates , 1999, Molecular medicine.

[12]  G. Cotsarelis,et al.  Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex , 2000, Nature Biotechnology.

[13]  H. Maibach,et al.  Cigarette smoking, cutaneous vasculature and tissue oxygen: an overview , 1998, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[14]  L. Babiuk,et al.  Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[15]  C. Alving,et al.  Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.

[16]  E. Raz,et al.  Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Hoffman,et al.  The feasibility of targeted selective gene therapy of the hair follicle , 1995, Nature Medicine.

[18]  D. Liggitt,et al.  Topical gene delivery to murine skin. , 1999, The Journal of investigative dermatology.

[19]  Mary S. Wu,et al.  Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. , 2000, Vaccine.